Bellicum Inc. (NASDAQ: BLCM) stock gained by 28.38% in the current market trading session. Bellicum is a pharmaceutical business in the early stages of development that aims to cure diseases via controlled cell therapies.
>> 7 Top Picks for the Post-Pandemic Economy <<
BLCM stock’ Current Development
The University of Texas MD Anderson Cancer Center and Bellicum Pharmaceuticals declared today a major option and license agreement attempting to cover certain intellectual property and technology rights linked to Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, as well as the use of rimiducid which is an agent used to stimulate the safety switch. MD Anderson will have the possibility to include CaspaCIDe into certain cellular therapy initiatives under the terms of this agreement.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Bellicum’s CaspaCIDe safety switch could make it easier to use cell therapies in situations where cytokine release syndrome and neurotoxicity have been reported, in the search for new targets with on-target/off-tumor safety concerns, and in combination with next-generation greater potency cell therapy constructs.
Rick Fair, President, and CEO of BLCM stated,
They’re excited to broaden their CaspaCIDe partnership with MD Anderson to provide a larger range of cancer-related programmes. The switch technology, they believe, could improve the benefit/risk balance of cell treatments. They want to keep looking for ways to increase its application through external cooperation with other thought leaders in the sector.
Furthermore,
Each option is normally expected to be exercised upon out-licensing of an MD Anderson programme that includes iC9. Bellicum will be paid upfront and will be allowed to be part of the third-party compensation given to MD Anderson. Bellicum will also get a royalty on global sales of the product in the single digits. The financial dealings are kept under wraps for the time being. Bellicum and MD Anderson have agreed to develop the first two programmes concurrently with the agreement’s execution. This deal builds on a prior one that covered CaspaCIDe’s usage in a specific MD Anderson cell therapy programme.